Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
FRC
First Republic Bank
FRC
|
+$734M |
| 2 |
Boeing
BA
|
+$493M |
| 3 |
Pfizer
PFE
|
+$478M |
| 4 |
UnitedHealth
UNH
|
+$440M |
| 5 |
Honeywell
HON
|
+$364M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$1.05B |
| 2 |
Advanced Micro Devices
AMD
|
+$447M |
| 3 |
TSMC
TSM
|
+$441M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$372M |
| 5 |
ExxonMobil
XOM
|
+$321M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.34% |
| 2 | Technology | 16.84% |
| 3 | Consumer Discretionary | 12.66% |
| 4 | Industrials | 10.11% |
| 5 | Consumer Staples | 9.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3651
Rapid Micro Biosystems
RPID
$106M
| $53K | ﹤0.01% |
+40,700
| New | +$52.9K |
|
3652
Spyre Therapeutics
SYRE
$8.54B
| $53K | ﹤0.01% |
7,244
+1,200
| +20% | +$13.2K |
|
3653
a.k.a. Brands
AKA
$124M
| $52K | ﹤0.01% |
8,017
+834
| +12% | +$12.6K |
|
|
AKTX
3654
Akari Therapeutics
AKTX
$13.8M
| $52K | ﹤0.01% |
354
+285
| +413% | +$89.8K |
|
3655
Eton Pharmaceutcials
ETON
$1.27B
| $52K | ﹤0.01% |
+13,400
| New | +$48.9K |
|
|
WPRT
3656
Westport Fuel Systems
WPRT
$33.4M
| $52K | ﹤0.01% |
5,414
-6,963
| -56% | -$71.3K |
|
|
YGMZ
3657
DELISTED
MingZhu Logistics Holdings
YGMZ
| $52K | ﹤0.01% |
353
-108
| -23% | -$18K |
|
|
QUOT
3658
DELISTED
Quotient Technology Inc
QUOT
| $52K | ﹤0.01% |
16,000
-251,500
| -94% | -$893K |
|
|
MDRR
3659
Medalist Diversified Inc
MDRR
$18.6M
| $51K | ﹤0.01% |
3,806
-2,713
| -42% | -$38.9K |
|
3660
Myomo
MYO
$39M
| $51K | ﹤0.01% |
68,600
+20,600
| +43% | +$12K |
|
3661
SCYNEXIS
SCYX
$48.1M
| $51K | ﹤0.01% |
2,138
+763
| +55% | +$10.1K |
|
3662
Tilray
TLRY
$618M
| $51K | ﹤0.01% |
+2,008
| New | +$57.3K |
|
|
EFTR
3663
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
| $51K | ﹤0.01% |
5,756
-3,040
| -35% | -$36.9K |
|
|
RAAS
3664
DELISTED
Cloopen Group Holding Limited American Depositary Shares (each representing six (6) Class A Ordinary Shares)
RAAS
| $51K | ﹤0.01% |
29,632
-35,028
| -54% | -$77.7K |
|
3665
Celularity
CELU
$18.4M
| $50K | ﹤0.01% |
8,020
+5,640
| +237% | +$45.4K |
|
|
KRKR
3666
36Kr Holdings
KRKR
$5.68M
| $50K | ﹤0.01% |
2,265
-985
| -30% | -$22.5K |
|
3667
Metalpha Technology Holding
MATH
$44.8M
| $50K | ﹤0.01% |
48,313
+10,713
| +28% | +$8.74K |
|
3668
Ostin Technology Group
OST
| $50K | ﹤0.01% |
218
-2
| -0.9% | -$500 |
|
|
ONCR
3669
DELISTED
Oncorus, Inc.
ONCR
| $50K | ﹤0.01% |
144,000
-142,936
| -50% | -$53.3K |
|
|
BON
3670
Bon Natural Life
BON
$8.94M
| $49K | ﹤0.01% |
138
+94
| +214% | +$35.8K |
|
|
NCEL
3671
NewcelX Ltd
NCEL
$18.8M
| $49K | ﹤0.01% |
80
+29
| +57% | +$16.9K |
|
|
TRVN
3672
DELISTED
Trevena, Inc.
TRVN
| $49K | ﹤0.01% |
2,821
+963
| +52% | +$31.4K |
|
3673
Satellogic
SATL
$531M
| $48K | ﹤0.01% |
+22,700
| New | +$70K |
|
3674
Benitec Biopharma
BNTC
$402M
| $47K | ﹤0.01% |
13,228
-8,862
| -40% | -$36.1K |
|
3675
Genprex
GNPX
$3.02M
| $47K | ﹤0.01% |
1
| – | – |
|
Similar funds
Renaissance Technologies's Q1 2023 Portfolio in Review
As of Q1 2023, Renaissance Technologies held 4,600 positions worth $75.4B, up 3.1% from $73.1B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Renaissance Technologies's Q1 2023 filing shows 524 new, 1,665 increased, 1,689 reduced and 668 closed positions. Its largest new stake was Honeywell: 1,937,917 shares worth $349M. The largest sale was Apple, an estimated $1.05B.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Technology and Consumer Discretionary.
- Renaissance Technologies's largest Q1 2023 buy was Honeywell: 1,937,917 shares worth $349M.
- Renaissance Technologies added most to First Republic Bank in Q1 2023, an estimated $734M increase.
- Renaissance Technologies's biggest Q1 2023 reduction was Apple, cutting an estimated $1.05B.
- Renaissance Technologies fully exited Advanced Micro Devices in Q1 2023, selling an estimated $447M.
- Renaissance Technologies's ten largest holdings make up 11% of its $75.4B portfolio in Q1 2023.
- Renaissance Technologies opened 524 new positions and closed 668 in Q1 2023.
- Renaissance Technologies's portfolio value rose 3.1% quarter-over-quarter to $75.4B.
Based on Renaissance Technologies's 13F filing for Q1 2023, filed 12 May 2023.